Drug facts

Is compounded semaglutide safe?

By ·Editor·Reviewed

Quick answer

Its safety has not been established — FDA does not review compounded drugs before they are sold. FDA has named three specific risks with compounded semaglutide: salt forms that are a different active ingredient, dosing errors — some of the reports FDA links to them required hospitalization — and quality. By 31 May 2026 it had received 990 adverse-event reports associated with compounded semaglutide.

The short version2

On the label — Wegovy / Ozempic

Wegovy and Ozempic: reviewed by FDA for safety, effectiveness and manufacturing quality, with every known risk on the label.

In a compounded vial

A compounded preparation: in FDA’s words, compounded drugs “are not FDA-approved,” and FDA “does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.”

So the honest answer to “is it safe?” is that nobody has checked the thing in your vial. What can be said is what FDA has seen go wrong, and what the drug carries whoever makes it.

The three risks FDA has named3

1. It may not be the same ingredient. FDA says some semaglutide sold by compounders “may be the salt forms,” including semaglutide sodium and semaglutide acetate, which are “different active ingredients than are used in the approved drugs.” FDA says it has no information on whether they behave the same, and knows of no lawful basis for compounding with them. More on which semaglutide is in the vial.

2. The dose goes wrong. FDA reports adverse events, “some requiring hospitalization,” that may be related to dosing errors with compounded injectable semaglutide — patients measuring the wrong amount, and in some cases health care professionals miscalculating it. It also reports events that may be related to prescriptions beyond the approved label: bigger doses, more frequent doses, or faster increases. The label’s schedule is on the dosage chart; measuring from a vial is on units and milligrams.

3. The preparation and its handling. FDA’s general warning about compounding is that poor practices can mean contamination or “a drug that contains too much or too little active ingredient.”2 For GLP-1s it adds that a multi-dose vial should be discarded 28 days after first use, that a vial arriving warm should not be used, and that it keeps an import alert to stop GLP-1 ingredients with potential quality concerns entering the country — see how long compounded semaglutide lasts.

What semaglutide itself carries1

These attach to the molecule and apply to a compounded vial exactly as to Wegovy. The label’s boxed warning is about thyroid C-cell tumors seen in rodents, with human relevance undetermined, and semaglutide is not to be used with a personal or family history of medullary thyroid carcinoma or MEN 2 — the warning, verbatim. The common reactions are gastrointestinal: nausea in 44% of trial participants against 16% on placebo — every reaction with its placebo rate. Low blood sugar alongside insulin or a sulfonylurea is covered in interactions.

The count3

990 reports of adverse events associated with compounded semaglutide had reached FDA by 31 May 2026. A report is not proof the drug caused the event, and a count of reports says nothing about how many people took it, so it is not a rate. It is, though, the clearest public sign of where things go wrong — and FDA’s own description points at the dose and the ingredient more than at the molecule.

FDA also writes to companies: of the 431 sellers in this index, 43 hold a warning letter matched to their operating company, each published in full on the trust page.4

What you can check

  • Which pharmacy, and which ingredient. Ask for the pharmacy’s name and whether the active ingredient is semaglutide or a salt form — four checks, ten minutes.
  • The concentration on the label, before every new vial, with the dose-in-units calculator.
  • The schedule: 0.25 mg for four weeks, then steps no closer than four weeks apart.
  • The cold chain and the 28 days. Refuse a warm delivery; discard an opened vial after four weeks.
  • Anything added, such as B12 — what an add-in changes.

The background — what a compounded vial is and who may make it — is on what compounded semaglutide is.

Questions

Is compounded semaglutide safe?
Its safety has not been established: FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed. FDA has named three risks with compounded semaglutide — salt forms that are a different active ingredient, dosing errors, and preparation quality — on top of the risks the drug itself carries.
What are the dangers of compounded semaglutide?
FDA has reported adverse events, some requiring hospitalization, that may be related to dosing errors with compounded semaglutide, and warns that some compounders use salt forms such as semaglutide sodium or acetate, which are different active ingredients. The drug itself carries a boxed warning for thyroid C-cell tumors and common gastrointestinal side effects.
How many adverse events has FDA received for compounded semaglutide?
990 reports as of 31 May 2026, according to FDA. A report is not proof that the drug caused the event.
Is compounded semaglutide safer than Wegovy or Ozempic?
There is no evidence that it is. Wegovy and Ozempic were reviewed by FDA for safety, effectiveness and manufacturing quality; a compounded preparation was not, and may not even contain the same form of the active ingredient.

Sources

  1. FDA prescribing information for WEGOVY (semaglutide), boxed warning and sections 4–6, as quoted on this site's drug-facts pages DailyMed
  2. FDA, Compounding and the FDA: Questions and Answers, content current as of 09/16/2025 FDA
  3. FDA, 'FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss', content current as of 09/01/2026 FDA
  4. This site's price index — FDA warning letters matched to sellers on the operating entity Read it